Abbott seeks U.S . Acceptance for HE4 assay to monitor recurrence/progression of epithelial ovarian cancer A fresh diagnostic tool physicians can use to monitor sufferers for the most typical form of ovarian cancers may soon be accessible in the United States. Research of known ovarian malignancy biomarkers discovered that HE4, which includes been detected in high levels in the bloodstream of some ovarian cancer patients, shows the best sensitivity and specificity of any additional marker and is definitely the best solitary marker for stage 1 of the condition. The ability to monitor the recurrence or progression of ovarian cancer is a crucial part of patient treatment.